"Buffalo Biomedical Technology co., Ltd." participated in the 2021 Digital RESI conference and reported the company's current status and future plans to investors .
Buffalo Biotech is a pre-clinical-stage company offering novel lung lavage therapeutics (Vigor® solution) for acute respiratory distress syndrome (ARDS), and Buffalo Biotech is the first to develop a unique physical therapy method to overcome no pharmacologic therapy problem for ARDS. Animal studies demonstrated reductions: 25% PMNL infiltration, 25% intra alveolar edema, and 50% mortality. Buffalo Biotech is seeking a $1.5M USD Pre-series A Round to start Vigor® solution first-in-Human safety clinical trial in Taiwan.